Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plastic Surgery Involvement in Index Posterior Spine Surgery Reduces Complication Rates.

Annals of plastic surgery·2026

Same author

Feasibility of Ultrasound-Guided Hydrodissection for Tenolysis of Adhesions Following Digital Flexor Tendon Repair.

Annals of plastic surgery·2026

Same author

Optimized Neurotherapy With Electrical Stimulation: Combined Peripheral Nerve Stimulation and Nerve Management Procedures for Postamputation Pain.

Annals of plastic surgery·2026

Same author

Flowable Extracellular Matrix Hydrogel to Prevent Adhesion Formation Following Flexor Tendon Repair: A Preclinical Study.

Plastic and reconstructive surgery·2026

Same author

Personality and Perception: A Qualitative Investigation of Factors That Shape Mentorship Satisfaction Among Hand Surgery Fellows.

Journal of hand surgery global online·2026

Same author

The Role of the Hand Surgeon in the Management of Self-Injurious Behavior: A Guideline for Comprehensive Care and Patient Safety.

The Journal of hand surgery·2025

Search research articles

Related Experiment Videos

Beta blocker specificity: a building block toward personalized medicine.

Brent R DeGeorge¹, Walter J Koch

¹Center for Translational Medicine and George Zallie and Family Laboratory for Cardiovascular Gene Therapy, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

The Journal of Clinical Investigation

|January 4, 2007

Summary

Genetic variations in beta-1 adrenergic receptors (beta-AR) influence heart failure patient responses to beta blockers. A specific amino acid change enhances receptor function and carvedilol effectiveness, paving the way for personalized medicine.

Related Experiment Videos

Area of Science:

Pharmacology
Cardiology
Genetics

Background:

Beta blockers are crucial for treating chronic heart failure (HF).
Patient responses to beta blockers vary significantly.
Genetic differences in beta-1 adrenergic receptors (beta-AR) are implicated in this variability.

Purpose of the Study:

To investigate how a specific genetic variation in beta-1 AR affects patient response to beta blockers.
To understand the mechanistic basis for variable responses to carvedilol in heart failure.

Main Methods:

The study focused on a single amino acid change in the beta-1 AR.
Analysis of structural conformation and functional response to carvedilol.

Main Results:

A single amino acid alteration in beta-1 AR was found to modify its structural conformation.
This change improved the receptor's functional response to the beta blocker carvedilol.
The findings offer a potential explanation for differential patient responses to carvedilol and other beta blockers.

Conclusions:

Genetic heterogeneity of beta-1 AR influences therapeutic outcomes in heart failure patients.
Understanding these genetic factors can lead to personalized medicine approaches.
Tailored therapies based on patient genotype may optimize beta blocker treatment for heart failure.